What the FDA labels say about taking them together
Aliskiren and irbesartan
Irbesartan's FDA label of August 6, 2026 names aliskiren in its contraindications section; aliskiren's label does not name irbesartan itself but warns about its class (ARBs (angiotensin II receptor blockers)). The irbesartan label: “Do not coadminister aliskiren with AVAPRO in patients with diabetes.”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the irbesartan FDA label on DailyMed (effective August 6, 2026, Macleods Pharmaceuticals Limited).
What does the aliskiren label say about irbesartan?
Aliskiren's label does not name irbesartan itself; it warns about its class (ARBs (angiotensin II receptor blockers)):
Aliskiren label, warnings and precautionsRenal Impairment/Hyperkalemia/Hypotension when Tekturna is Given in Combination with ARBs or ACEIs Tekturna is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension.
Aliskiren label, contraindicationsCONTRAINDICATIONS Do not use Tekturna with ARBs or ACEIs in patients with diabetes [see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.3 )].
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the irbesartan label say about aliskiren?
Irbesartan label, contraindicationsDo not coadminister aliskiren with irbesartan tablets in patients with diabetes.
Irbesartan label, drug interactionsBlockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Avapro, NDA020757), Sanofi-Aventis U.S. LLC, effective August 24, 2026 (SPL set 7885b2a8-be4e-48ab-8113-4e6ab791eb98), via openFDA
Source: FDA drug label (Irbesartan), Macleods Pharmaceuticals Limited, effective August 6, 2026 (SPL set e8635a1c-ae06-4e23-99f7-e704f91d6f43), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Irbesartan | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Chronic kidney disease |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.107 per tablet 150 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once